Related Experiment Video
Updated: Feb 12, 2026
A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces
Published on: January 7, 2020
The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
Ines Garces de Los Fayos Alonso1,2,3, Huan-Chang Liang4, Suzanne D Turner5
1Ludwig Boltzmann Institute for Cancer Research, 1090 Vienna, Austria. Ines.Garces@lbicr.lbg.ac.at.
Abstract:
The Activator Protein-1 (AP-1) transcription factor (TF) family, composed of a variety of members including c-JUN, c-FOS and ATF, is involved in mediating many biological processes such as proliferation, differentiation and cell death. Since their discovery, the role of AP-1 TFs in cancer development has been extensively analysed. Multiple in vitro and in vivo studies have highlighted the complexity of these TFs, mainly due to their cell-type specific homo- or hetero-dimerization resulting in diverse transcriptional response profiles. However, as a result of the increasing knowledge of the role of AP-1 TFs in disease, these TFs are being recognized as promising therapeutic targets for various malignancies. In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.
Insights
Activator Protein-1 (AP-1) transcription factors regulate cell processes and are implicated in cancer. This review explores their role in CD30-positive lymphomas, highlighting their therapeutic potential.
Area of Science:
- Molecular Biology
- Oncology
Background:
- The Activator Protein-1 (AP-1) transcription factor (TF) family, including c-JUN, c-FOS, and ATF, regulates critical biological processes like proliferation, differentiation, and cell death.
- AP-1 TFs exhibit complex, cell-type specific homo- or hetero-dimerization, leading to diverse transcriptional outcomes and playing a significant role in cancer development.
Purpose of the Study:
- To review the impact of deregulated AP-1 TF expression in CD30-positive lymphomas.
- To highlight AP-1 TFs as potential therapeutic targets for malignancies.
Main Methods:
- Literature review focusing on AP-1 transcription factors.
- Analysis of studies investigating AP-1 TF roles in cancer, specifically CD30-positive lymphomas.
Main Results:
- AP-1 TFs are involved in mediating biological processes relevant to cancer.
- Deregulated expression of AP-1 TFs is observed in CD30-positive lymphomas.
- The complexity of AP-1 TF dimerization contributes to varied cellular responses.
Conclusions:
- AP-1 TFs are increasingly recognized as promising therapeutic targets for various malignancies.
- Understanding AP-1 TF dysregulation in lymphomas like Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma is crucial for developing targeted therapies.
Related Concept Videos
02:47Protein Families
02:47Protein Families
01:57Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
02:15SN1 Reaction: Stereochemistry
In the first step of an SN1 reaction, the bond between the electrophilic carbon and the leaving group ionizes to generate the carbocation intermediate. The second step of the mechanism is the nucleophilic attack.
In the formed carbocation, the positively charged carbon is sp2 hybridized with a trigonal planar geometry. As all the three substituents lie on the same plane, a plane of symmetry for the...
02:05SN1 Reaction: Kinetics
However, Sir Christopher Ingold and Edward D. Hughes, who studied the kinetics of various nucleophilic substitution reactions, noticed that a tertiary alkyl halide does undergo a nucleophilic substitution reaction in the presence of a weak nucleophile. While studying the substitution...
02:25SN1 Reaction: Mechanism
Firstly, the haloalkane ionizes to generate a carbocation intermediate and a halide ion. This heterolytic cleavage is highly endothermic with large activation energy. The ionization of the substrate, facilitated by a...